Literature DB >> 15367042

National trends in the outpatient treatment of anxiety disorders.

Mark Olfson1, Steven C Marcus, George J Wan, Erika C Geissler.   

Abstract

BACKGROUND: Recent advances in psychotherapy and pharmacotherapy have increased the number of treatment options for anxiety disorders. This article examines changes in outpatient treatment of anxiety disorders in the United States between 1987 and 1999.
METHOD: Analyses are presented of service utilization data from 2 nationally representative surveys of the general population: the 1987 National Medical Expenditure Survey and the 1999 Medical Expenditure Panel Survey. Respondents were selected who made 1 or more outpatient visits for the treatment of an anxiety disorder (ICD-9/DSM-IV: 300.0, 300.2, 300.3, or 308.3). The rates of treatment, psychotropic medication use, psychotherapy, number of outpatient treatment visits, type of provider, and source of payment were determined.
RESULTS: The rate of outpatient treatment for anxiety disorders increased from 0.43 per 100 persons in 1987 to 0.83 in 1999 (p <.001). Among those treated for an anxiety disorder, the proportion that received psychotropic medications increased from 52.1% to 69.9% (p =.008). Among treated patients, antidepressant use increased from 18.3% to 44.9% (p <.0001), while use of benzodiazepines (42.3% to 31.7%, p =.09) and psychotherapy (60.5% to 48.0%, p =.07) tended to decline. A decreasing proportion of mean treatment expenditures was covered by self-payment (53.2% to 31.5%, p <.0001).
CONCLUSION: Between 1987 and 1999, there was an increase in the proportion of the population who received outpatient treatment for anxiety disorders. Among patients receiving care, treatment became characterized by greater use of psychotropic medications, especially antidepressant medications, with nonsignificant trends toward less common use of psychotherapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15367042     DOI: 10.4088/jcp.v65n0903

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  17 in total

1.  Challenges and Successes in Dissemination of Evidence-Based Treatments for Posttraumatic Stress: Lessons Learned From Prolonged Exposure Therapy for PTSD.

Authors:  Edna B Foa; Seth J Gillihan; Richard A Bryant
Journal:  Psychol Sci Public Interest       Date:  2013-05

2.  Correlates and psychiatric disorders associated with psychotropic drug use in Taiwan.

Authors:  I-Chia Chien; Shin-Huey Bih; Ching-Heng Lin; Yiing-Jenq Chou; Wen-Guang Lee; Cheng-Hua Lee; Pesus Chou
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2009-11-20       Impact factor: 4.328

3.  Psychotherapy Claims Surrounding Pharmacotherapy Initiation in Children and Adolescents with Anxiety Disorders.

Authors:  Greta A Bushnell; Stacie B Dusetzina; Scott N Compton; Bradley N Gaynes; M Alan Brookhart; Til Stürmer
Journal:  J Child Adolesc Psychopharmacol       Date:  2018-12-19       Impact factor: 2.576

4.  Has increased provision of treatment reduced the prevalence of common mental disorders? Review of the evidence from four countries.

Authors:  Anthony F Jorm; Scott B Patten; Traolach S Brugha; Ramin Mojtabai
Journal:  World Psychiatry       Date:  2017-02       Impact factor: 49.548

5.  Benzodiazepine Treatment and Fracture Risk in Young Persons With Anxiety Disorders.

Authors:  Greta A Bushnell; Tobias Gerhard; Stephen Crystal; Mark Olfson
Journal:  Pediatrics       Date:  2020-06-04       Impact factor: 7.124

6.  Psychotropic medication use mediates the relationship between mood and anxiety disorders and obesity: findings from a nationally representative sample.

Authors:  Jasper A J Smits; David Rosenfield; Amber A Mather; Candyce D Tart; Christine Henriksen; Jitender Sareen
Journal:  J Psychiatr Res       Date:  2010-11       Impact factor: 4.791

7.  Results of a naturalistic longitudinal study of benzodiazepine and SSRI use in the treatment of generalized anxiety disorder and social phobia.

Authors:  Russell G Vasile; Steven E Bruce; Robert M Goisman; Maria Pagano; Martin B Keller
Journal:  Depress Anxiety       Date:  2005       Impact factor: 6.505

8.  Medicare inpatient treatment for elderly non-dementia psychiatric illnesses 1992--2002; length of stay and expenditures by facility type.

Authors:  Donald R Hoover; Ayse Akincigil; Jonathan D Prince; Ece Kalay; Judith A Lucas; James T Walkup; Stephen Crystal
Journal:  Adm Policy Ment Health       Date:  2008-02-22

9.  Psychotropic Drug Use in São Paulo, Brazil--An Epidemiological Survey.

Authors:  Maria Ines Quintana; Sergio Baxter Andreoli; Marcela Poctich Peluffo; Wagner Silva Ribeiro; Marcelo M Feijo; Rodrigo Affonseca Bressan; Evandro S F Coutinho; Jair de Jesus Mari
Journal:  PLoS One       Date:  2015-08-07       Impact factor: 3.240

10.  Adherence to antidepressant treatment among privately insured patients diagnosed with depression.

Authors:  Ayse Akincigil; John R Bowblis; Carrie Levin; James T Walkup; Saira Jan; Stephen Crystal
Journal:  Med Care       Date:  2007-04       Impact factor: 2.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.